Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies"). New research led by Boston Children's Hospital challenges the current ...

Conventional treatments of Alzheimer's disease, one of the most common forms of dementia, have been largely focused on ...

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano Med Promising tumor ...

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in patients with advanced solid tumors ...

In the battle against aggressive breast cancer, a once-elusive target is now within reach—thanks to a breakthrough from a team from the Faculty of Medicine at Hebrew University. Dr. Raphael Benhamou ...

Every medication in your cabinet, every material in your phone's battery, and virtually every compound that makes modern life work started as a molecular guess, with scientists hypothesizing that a ...

Dermatology Nursing. 2005;17(3):181-186. Currently, bevacizumab is in clinical trials in renal cell carcinoma, nonsmall cell lung cancer, and metastatic breast cancer. Thera peutic dosages are still ...

Researchers at City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S ...

Automatically numbering and weighting electronic states instead of taking averages improves estimates of target molecular orbitals.

In a major stride toward tackling aggressive breast cancer, researchers from The Hebrew University of Jerusalem have developed druglike molecules that degrade a previously “undruggable” cancer-driving ...